研究单位：[1]Department of Hematology, Xinqiao Hospital ChongQing, Chongqing, China, 400037[2]Gracell Biotechnology Shanghai Co., Ltd.[3]920th Hospital of Joint Logistics Support Force of People's Liberation Army of China[4]The Second Affiliated Hospital of Chongqing Medical University[5]The Affiliated Hospital Of Guizhou Medical University[6]Central South University[7]First Affiliated Hospital of Kunming Medical University[8]The General Hospital of Western Theater Command[9]Second Affiliated Hospital of Xi'an Jiaotong University[10]Nanfang Hospital of Southern Medical University[11]Fujian Medical University Union Hospital[12]The First Affiliated Hospital of Anhui Medical University[13]Tang-Du Hospital
研究目的：
The prognosis of patients with relapsed and/or refractory T-cell hematologic malignancies is poor due to lacking sufficient treatment.Anti-CD(cluster of differentiation antigen)19 CAR(chimeric antigen receptor)-T cell therapies are efficient for patients with B-cell hematologic malignancies. As for T-cell hematologic malignancies, CD7 is a promising target expressed on most malignant T cells. The outcome of CD-7 CAR-T cell therapy pre-clinical experiments is cheerful.however, how to select the functional T cells from the malignant T cells is a challenge. In addition to this, auto-CAR-T cell therapy is not affordable for the majority of patients. Using T cells aphesis from healthy donors edited to avoid rejection of the host as the material of anti-CD7 universal CAR-T cells could be accessible and affordable, which is adapted for patients with CD7+ relapsed and/or refractory T/NK-cell hematologic malignancies.
